These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 25402275)

  • 21. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
    Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
    J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
    Xue M; Li T; Wang Y; Chang Y; Cheng Y; Lu Y; Liu X; Xu L; Li X; Yu X; Sun B; Chen L
    Clin Sci (Lond); 2019 Aug; 133(15):1705-1720. PubMed ID: 31337673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
    Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
    J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
    Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway.
    Zhou Y; Wu W
    Cell Physiol Biochem; 2017; 41(6):2503-2512. PubMed ID: 28472796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.
    Hammoudi N; Jeong D; Singh R; Farhat A; Komajda M; Mayoux E; Hajjar R; Lebeche D
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):233-246. PubMed ID: 28643218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
    Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
    J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antioxidant icariside II combined with insulin restores erectile function in streptozotocin-induced type 1 diabetic rats.
    Wang L; Xu Y; Li H; Lei H; Guan R; Gao Z; Xin Z
    J Cell Mol Med; 2015 May; 19(5):960-9. PubMed ID: 25781208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.
    Madonna R; Doria V; Minnucci I; Pucci A; Pierdomenico DS; De Caterina R
    J Cell Mol Med; 2020 Nov; 24(21):12331-12340. PubMed ID: 32940423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
    Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
    Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lycopene attenuates endothelial dysfunction in streptozotocin-induced diabetic rats by reducing oxidative stress.
    Zhu J; Wang CG; Xu YG
    Pharm Biol; 2011 Nov; 49(11):1144-9. PubMed ID: 21517710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mangiferin suppressed advanced glycation end products (AGEs) through NF-κB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats.
    Hou J; Zheng D; Fung G; Deng H; Chen L; Liang J; Jiang Y; Hu Y
    Can J Physiol Pharmacol; 2016 Mar; 94(3):332-40. PubMed ID: 26751764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant defense system in brain tissue of diabetic rats.
    Yaribeygi H; Hemmati MA; Nasimi F; Pakdel R; Jamialahmadi T; Sahebkar A
    Behav Brain Res; 2024 Mar; 460():114830. PubMed ID: 38141785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.